CAMBRIDGE, England, June 7, 2010 /PRNewswire/ -- O2h (Ahmedabad, India) is pleased to announce the signing of an agreement with Karyopharm Therapeutics, Inc. (Newton, Massachusetts, USA) under which O2h will provide Karyopharm discovery services to advance Karyopharm's lead small molecule program toward the nomination of a development candidate.
Dr. Sharon Shacham, co-founder and CSO of Karyopharm, said, "O2h has an excellent reputation as an efficient and high quality discovery services provider. We look forward to working with the O2h team to further the progress of our first program as we continue to build our proprietary expertise developing drugs targeting the nuclear pore complex machinery."
Sunil Shah, CEO of O2h, said, "It has been a pleasure working with Dr. Shacham as she is one of the most dynamic and focused drug discovery leaders that I have met. Leveraging Dr. Shacham's proprietary and proven approach to drug discovery, I'm optimistic that Karyopharm will be a great success."
About Oxygen Healthcare Ltd
O2h is a 5-year-old discovery services company co-located in Cambridge, UK and Ahmedabad, India. The Indian operations provide a high level of chemistry expertise while the UK office provides project management support. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services lab-units and ADME. Further information on O2h can be found at http://www.o2h.com.
Contact information: Dr. Ekta Ahuja firstname.lastname@example.org OXYGEN HEALTHCARE LTD 23 Cambridge Science Park CB4 0EY
About Karyopharm Therapeutics, Inc.
Karyopharm is the first company to focus on discovering and developing therapies by targeting the nuclear pore complex machinery. The company is rapidly advancing small molecules that modulate the activity of critical pathways in cancer, viral and inflammatory diseases. IND enabling studies of its first program targeting CRM1 will begin this year. For more information please visit http://www.karyopharm.com.
Contact Information: Sharon Shacham, PhD Co-founder and Chief Scientific Officer Karyopharm Therapeutics, Inc. email@example.com